Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

NCT02116712 is registered in ClinicalTrials.gov with Tony Eissa as lead sponsor.

NCT NCT02116712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02116712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Lead sponsor
Tony Eissa
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2014
Completion date
July 31, 2015
Enrollment
9 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary lymphangioleiomyomatosis